Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2016

This report fulfills the annual reporting mandate from the Patient Protection and Affordable Care Act (ACA) for 2016. The ACA requires OIG to conduct a study of the extent to which formularies used by Medicare Part D plans (i.e., stand-alone prescription drug plans and Medicare Advantage prescription drug plans) include drugs commonly used by full benefit dual eligible individuals (i.e., individuals who are eligible for both Medicare and full Medicaid benefits). Pursuant to the ACA, OIG must annually issue a report with recommendations as appropriate. This is the sixth report the OIG has produced to meet this mandate.